Phase 3 N=35 Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
ADHD
Primary: Brain Activation — 0.19; -0.08 Beta weights of contrast — p==0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=11 An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
Generalized Pustular Psoriasis
Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) — 7 Participants
Phase 3 N=787 Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population — 37.7; 26.0 percentage of participants…
Phase 3 N=941 Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT)…
Phase 3 N=223 Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)
Total Knee Replacement · Total Hip Replacement
Primary: Pain Measured by the Numeric Rating Scale — 3.34; 3.32 units on a scale
Phase 3 N=407 Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Obesity
Primary: Percentage Change in Body Weight — -14.2; -2.5 Percentage change in body weight — p=<0.0001
Phase 3 N=48 Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
Bone Marrow Edema
Primary: Reduction of the Edema Area — 64.53; 23.97 percentage of edema volume — p==0.006
Phase 3 N=502 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
Primary: Overall Survival — 11.5; 9.5 Months — p=0.0038
Phase 3 N=627 Safety of REL-1017 for Major Depressive Disorder
Major Depressive Disorder
Primary: Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs) — 350 participants
Phase 3 N=3,548 A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
SARS-CoV-2
Primary: Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 — 537.7; 302.8 AU/mL
Phase 3 N=231 Eptinezumab in Participants With Episodic Cluster Headache
Cluster Headache, Episodic
Primary: Change From Baseline in the Number of Weekly Cluster Headache (CH) Attacks, Averaged Over Weeks 1-2 — -4.0; -4.6 Number of Weekly Attacks — p=0.5048
Phase 3 N=109 A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Pulmonary Tuberculosis
Primary: Proportion of Treatment Failure (Unfavorable Outcome), Defined as Bacteriologic Failure or Relapse or Clinical Failure (Derived) Through Follow-up Until 6 Months After…
Phase 3 N=957 MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
Glabellar Lines · Lateral Canthal Lines
Primary: Number of Participants Who Experienced Any Adverse Event (AE) — 39; 39; 80; 89 Participants
Phase 3 N=118 Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
Fabry Disease
Primary: Neuropathic Pain Monthly Score: Change From Baseline to Month 6 — -1.64; -2.05 score on a scale — p=0.3189
Phase 3 N=740 A Study of Brexpiprazole in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B). — -8.5…